Raymond A. Pagliarini, Ph.D.
Affiliations: | Novartis, Basel, Basel-Stadt, France |
Google:
"Raymond Pagliarini"Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Gao X, Wang Y, Ribeiro CF, et al. (2022) Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Molecular Cancer Research : McR |
Ye LF, Reznik E, Korn JM, et al. (2020) Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery. Oncotarget. 11: 443-451 |
Li H, Ning S, Ghandi M, et al. (2019) The landscape of cancer cell line metabolism. Nature Medicine. 25: 850-860 |
Liu H, Golji J, Brodeur LK, et al. (2018) Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nature Medicine |
Zhao Q, Manning JR, Sutton J, et al. (2018) Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. Acs Medicinal Chemistry Letters. 9: 746-751 |
Cho YS, Levell JR, Liu G, et al. (2017) Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. Acs Medicinal Chemistry Letters. 8: 1116-1121 |
McDonald ER, de Weck A, Schlabach MR, et al. (2017) Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell. 170: 577-592.e10 |
Levell JR, Caferro T, Chenail G, et al. (2017) Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. Acs Medicinal Chemistry Letters. 8: 151-156 |
Xie X, Baird D, Bowen K, et al. (2017) Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity. Structure (London, England : 1993) |
Mounir Z, Korn JM, Westerling T, et al. (2016) ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. Elife. 5 |